HGH vs VIP
FDA Approved vs Extensively Studied
synergistic Mechanism-based · 50% HGH reduces inflammation while VIP promotes tissue repair. Reducing inflammation creates a more favorable environment for healing.
Molecular Data
HGH VIP
Weight 22,124 Da 3,326 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) 1-2 minutes
Chain 191 amino acids 28 amino acids
Type Single-chain polypeptide with two disulfide bridges Neuropeptide
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
VIP
01 Potent vasodilation and blood pressure reduction
02 Strong anti-inflammatory effects
03 Immunomodulation (Th1-Th2 balance)
04 Neuroprotective effects
05 Bronchodilation
06 Cardioprotective (positive inotropic effects)
07 Insulin secretion enhancement (glucose-dependent)
08 Gut barrier and permeability regulation
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
VIP
50-100 mcg per dose (up to 200 mcg in research protocols) / 1-2 times daily due to very short 2-minute half-life
General use 50-100 mcg 1-2x daily
Research protocols 100-200 mcg As directed
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
VIP
Vasodilation (flushing, warmth)
Hypotension
Increased heart rate
Gastrointestinal effects (diarrhea possible)
Headache
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Severe hypotension
VIPoma or related tumors
Pregnancy or breastfeeding
Severe cardiac conditions
Research Evidence
HGH VIP
Status FDA Approved Extensively Studied
References 4 studies 4 studies
Latest 2024 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.